NEW YORK (GenomeWeb) – Within a large pharmacogenetic study ongoing at several Indiana institutions, researchers are aiming to tackle the issues that have kept personalized medicine approaches from reaching disadvantaged communities.

Earlier this month, Eskenazi Health, the Indiana Institute for Personalized Medicine (IIPM), the Indiana University School of Medicine, and the Regenstrief Institute announced the launch of a 6,000-patient prospective trial to study the impact of preemptive pharmacogenetic testing in a community healthcare setting.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.

New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.

The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.

In Nature this week: protein-coding variants associated with body-fat distribution, and more.